Mizuho Forecasts Strong Price Appreciation for WAVE Life Sciences (NASDAQ:WVE) Stock

WAVE Life Sciences (NASDAQ:WVE) had its price target increased by research analysts at Mizuho from $22.00 to $27.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Mizuho’s price target indicates a potential upside of 335.48% from the company’s previous close.

Several other brokerages have also issued reports on WVE. Wall Street Zen lowered shares of WAVE Life Sciences from a “hold” rating to a “sell” rating in a research note on Saturday, February 7th. Oppenheimer upped their price objective on shares of WAVE Life Sciences from $24.00 to $32.00 and gave the stock an “outperform” rating in a report on Tuesday, December 16th. Leerink Partners reaffirmed an “outperform” rating on shares of WAVE Life Sciences in a research note on Monday, December 8th. Cantor Fitzgerald lifted their target price on shares of WAVE Life Sciences from $34.00 to $41.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Citigroup boosted their price target on WAVE Life Sciences from $16.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, WAVE Life Sciences currently has a consensus rating of “Moderate Buy” and an average target price of $33.31.

WAVE Life Sciences Stock Down 49.6%

Shares of WVE stock opened at $6.20 on Wednesday. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of -5.08 and a beta of -1.77. The business’s fifty day moving average is $13.08 and its 200 day moving average is $11.20. WAVE Life Sciences has a twelve month low of $5.02 and a twelve month high of $21.73.

WAVE Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.02). WAVE Life Sciences had a negative net margin of 478.35% and a negative return on equity of 85.69%. The firm had revenue of $17.25 million for the quarter, compared to analysts’ expectations of $15.68 million. Equities research analysts expect that WAVE Life Sciences will post -1.14 earnings per share for the current fiscal year.

Insider Activity

In other WAVE Life Sciences news, insider Chris Francis sold 33,194 shares of the firm’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $15.05, for a total transaction of $499,569.70. Following the completion of the sale, the insider directly owned 61,867 shares in the company, valued at approximately $931,098.35. This trade represents a 34.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Paul Bolno sold 10,480 shares of WAVE Life Sciences stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $13.45, for a total transaction of $140,956.00. Following the completion of the transaction, the chief executive officer directly owned 275,520 shares of the company’s stock, valued at $3,705,744. This trade represents a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 61,748 shares of company stock valued at $907,809. Company insiders own 23.98% of the company’s stock.

Hedge Funds Weigh In On WAVE Life Sciences

Hedge funds have recently added to or reduced their stakes in the company. Hsbc Holdings PLC boosted its stake in WAVE Life Sciences by 52.1% during the 4th quarter. Hsbc Holdings PLC now owns 16,990 shares of the company’s stock valued at $291,000 after purchasing an additional 5,823 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of WAVE Life Sciences in the fourth quarter worth $176,000. Virtu Financial LLC purchased a new position in shares of WAVE Life Sciences in the fourth quarter worth $457,000. Invesco Ltd. lifted its holdings in shares of WAVE Life Sciences by 27.5% during the fourth quarter. Invesco Ltd. now owns 179,932 shares of the company’s stock valued at $3,059,000 after purchasing an additional 38,806 shares in the last quarter. Finally, Voloridge Investment Management LLC bought a new position in shares of WAVE Life Sciences during the fourth quarter valued at $12,278,000. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting WAVE Life Sciences

Here are the key news stories impacting WAVE Life Sciences this week:

• Positive Sentiment: The company reported interim Phase 1 INLIGHT data showing placebo‑adjusted improvements at six months — visceral fat down ~14%, total fat down ~5%, lean mass +2%, waist circumference down ~3.3% — and continued safety/tolerability. These signals support the drug’s mechanistic promise (body‑composition benefit). Read More.
• Positive Sentiment: Some analysts and outlets highlight the trial’s body‑composition gains and safety profile as a reason to view the selloff as a buying opportunity; Mizuho recently raised its price target and Truist upgraded the stock. Read More.
• Neutral Sentiment: Coverage emphasizes the distinction between clinically meaningful visceral‑fat reductions and the modest absolute weight loss observed — important context for assessing commercial potential but ambiguous for near‑term valuation. Read More.
• Negative Sentiment: Market reaction: the higher‑dose results were widely described as disappointing because they did not produce clear additional weight loss, prompting a massive selloff and extreme intraday volume as investors exited on efficacy concerns and lower near‑term commercial prospects. Read More.
• Negative Sentiment: Multiple news outlets framed the update as “underwhelming” and noted the tiny (~1%) change in body weight over six months despite visceral‑fat gains — headlines and analyst downgrades amplified selling pressure. Read More.
• Negative Sentiment: Legal risk: a plaintiff firm is publicly soliciting shareholders about potential securities claims tied to the company’s disclosures, adding regulatory and litigation uncertainty that can prolong downward pressure. Read More.

About WAVE Life Sciences

WAVE Life Sciences is a clinical-stage genetic medicines company focused on the discovery and development of stereopure oligonucleotide therapies designed to address serious diseases with high unmet medical need. Leveraging proprietary chemistry and precision synthesis, WAVE engineers drug candidates with defined stereochemistry to optimize potency, safety and manufacturability. This approach aims to enhance target specificity and improve therapeutic profiles compared with traditional oligonucleotide medicines.

The company’s pipeline includes programs in neuromuscular disorders such as Duchenne muscular dystrophy and neurodegenerative conditions including Huntington’s disease, as well as early-stage cardiovascular and liver indications.